Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302807 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 931
- Enrollment target
NCT02302807 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 931 participants.
The verdict
NCT02302807, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 931 participants
- Enrollment target
Study Summary
This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Vinflunine
- DRUG Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 931 participants |
| Start Date | 2015-01-13 |
| Est. Completion | 2018-11-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302807
The ClinicalTrials.gov registry entry for NCT02302807 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 931 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT02302807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02302807 about?
NCT02302807 is a clinical study titled "A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]". This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or follow...
What is the current status of trial NCT02302807?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 931 participants. The study started on 2015-01-13. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT02302807?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), Vinflunine (DRUG), Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody (DRUG).
Who is sponsoring clinical trial NCT02302807?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.